Marshall Wace, LLP Repligen Corp Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Repligen Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 237,222 shares of RGEN stock, worth $38.2 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
237,222
Previous 364,551
34.93%
Holding current value
$38.2 Million
Previous $46 Million
23.18%
% of portfolio
0.05%
Previous 0.06%
Shares
24 transactions
Others Institutions Holding RGEN
# of Institutions
489Shares Held
54.3MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.22 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$1.03 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$812 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$261 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$229 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.93B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....